Email this article 
Potential algorithm of prostate cancer management during the pandemic of coronavirus infection (COVID-19)
- Authors: Matveev V.B.1, Volkova M.I.1, Trofimova O.P.1, Tkachev S.I.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 16, No 1 (2020)
- Pages: 124-128
- Section: TOPICAL PROBLEM
- Published: 30.03.2020
- URL: https://oncourology.abvpress.ru/oncur/article/view/1293
- DOI: https://doi.org/10.17650/1726-9776-2020-16-1-124-128
- ID: 1293
Cite item
Full Text
Abstract
The World Health Organization has announced the coronavirus infection pandemic (COVID-19), associated with a high risk of severe complications requiring intensive care. The following is a possible algorithm for the choice of treatment tactics for prostate cancer during the COVID-19 pandemic, aimed at achieving 3 main goals: reducing the risk of life-threatening complications of the tumor process, minimizing the risk of “crossing” the profiles of adverse events associated with prostate cancer treatment and viral infection, and diminishing the risk of COVID-19 contamination for prostate cancer patients. The proposed algorithm is a personal view of the authors and is not an official recommendation.
About the authors
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0001-7748-9527
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
M. I. Volkova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: mivolkova@rambler.ru
ORCID iD: 0000-0001-7754-6624
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
O. P. Trofimova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe Shosse, Moscow 115478 Russian Federation
S. I. Tkachev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0001-8965-8172
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
References
- Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6.
- Ueda M., Martins R., Hendrie P.C. et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020:1–4. doi: 10.6004/jnccn.2020.7560.
- Care of prostate cancer patients during the COVID-19 pandemic: recommendations of the NCCN. Available at: https://www.nccn.org/covid-19/pdf/ NCCN_PCa_COVID_guidelines.pdf.
- Gupta N., Bivalacqua T.J., Han M. et al. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to veryhigh-risk clinically localised prostate cancer. BJU Int 2019;124(2):268–74. doi: 10.1111/bju.14659.
- Denham J.W., Steigler A., Lamb D.S. et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12(5):451–9. doi: 10.1016/S1470-2045(11)70063-8.
- Widmark A., Gunnlaugsson A., Beckman L. et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019;394(10196):385–95. doi: 10.1016/S0140-6736(19)31131-6.
- Parker C.C., James N.D., Brawley C.D. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353–66. doi: 10.1016/S0140-6736(18)32486-3.
- Clinical Guidelines for the treatment of prostate cancer of the Association of Oncologists of Russia 2019. Available at: https://oncology-association.ru/newclinical-guidelines. (In Russ.).
- Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castrationsensitive prostate cancer. N Engl J Med 2019;381(1):13–24. doi: 10.1056/NEJMoa1903307.
- Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.
- Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. doi: 10.1016/S1470-2045(12)70560-0.
- de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. doi: 10.1016/S0140-6736(10)61389-X.
Supplementary files
